Citations

Clear

1011 citation(s) found for "Barry, WT".

Abstract 417: The Prognostic Value of Lactate in Cardiac Intensive Care Unit Patients With and Without Cardiac Arrest
Burstein, Barry , Ternus, Bradley , Barsness, Gregory W. , Vallabhajosyula, Saraschandra , Kashani, Kianoush , Jentzer, Jacob C.

Mayo Clinic

Circulation | June 21, 2021 | Volume: 140 | Issue: Suppl_2 | Pages: No page available

10.1161/circ.140.suppl_2.417 Get It

Introduction: Lactate is a known prognostic marker in critically ill patients, including patients with shock and cardiac arrest (CA). We sought to describe the association between admission lactate and hospital mortality in cardiac intensive care unit (CICU) patients, particularly those with CA. Methods: We retrospectively evaluated adult patients admitted to a tertiary care CICU from January 1, 2007, to April 30, 2018, with measured lactate on admission. We examined hospital mortality as a function of admission lactate level in patients with and without CA. Multivariable logistic regression was used to determine predictors of hospital mortality in the overall cohort, after adjustment for clinical characteristics, therapies, and illness severity. Results: We included 3,042 patients with a median age of 70 years (IQR 60-80), including 40.5% (n=1,233) females. There were 789 patients (26.1%) with a diagnosis of CA. The median APACHE-4 predicted mortality was 24.2% (IQR 10.9-50.7), and 50.8% (n=1546) were treated with vasoactive infusions. The median lactate on admission was 1.8 mmol/L (IQR 1.1-3.0). CICU mortality occurred in 478 (15.7%) patients) and hospital mortality occurred in 706 (23.2%) patients. Hospital mortality rose progressively as a function of admission lactate ( Figure ). On univariable analysis, lactate was associated with increased hospital mortality among the overall cohort (OR 1.36, CI 1.31-1.42, P < .001; AUROC 0.71), patients with CA (OR 1.33 (95% CI 1.25-1.41, P < .01; AUROC 0.73), and patients without CA (OR 1.27, CI 1.21-1.34, P < .01; AUROC 0.64). On multivariable analysis, lactate was one of the most significant predictors of hospital mortality (adjusted OR 1.13 per mmol/L, 95% CI 1.08-1.18, P < .001). Conclusions: Admission lactate levels are strongly associated with increased hospital mortality among CICU patients, especially those with CA. The prognostic value of lactate levels may help inform clinicians caring for CICU patients.
Abstract TP119: Credentialing of Interventionists in a Large Randomized Trial
Roubin, Gary S., Heck, Donald , Dabus, Guilherme , Jankowitz, Brian T. , Katzen, Barry T. , Gray, William A. , Matsumura, Jon S. , Hopkins, L. Nelson , Gamble, Dale M., Voeks, Jenifer H. , Luke, Sothear , Lal, Brajesh K. , Brott, Thomas G. , White, Christopher J. , Rosenfield, Kenneth , Dabus, Guilherme C. , Jovin, Tudor G. , Meschia, James F.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.tp119 Get It

Introduction: Outcomes from endovascular procedures are highly dependent on the experience and skill of the operating physician. The multi-disciplinary CREST-2 Interventional Management Committee (IMC) was charged with credentialing a cohort of skilled interventionists with adequate contemporary case volumes. Methods: Applicants were required to submit 25 consecutive cases completed within 5 years as primary operator out of a required total experience of ≥ 50 cases (≥ 20 for operators completing training). Interventionists not approved on initial review were asked to submit additional cases (with procedural angiograms), the number depending on quality and recent-quantity of the cases. Results: The IMC has had 102 meetings, and 283 interventionists have been evaluated: 104 (37%) interventionists were cardiologists, 64 (23%) vascular surgeons, 42 (15%) neurosurgeons, 32 (11%) neuroradiologists, 26 (9%) neurologists, 9 (3%) interventional radiologists, and 6 (2%) other. The mean total experience among the 226 interventionists with available information was 220±263 carotid stent cases (median 135; range 10-2500). A total of 7037 cases have been reviewed by the IMC, dating from August 2001 to April 2016, with 3366 symptomatic, 3541 asymptomatic and 130 undetermined. The range of cases reviewed per interventionist was 5 to 50. Of the 251 interventionists with sufficient periprocedural follow-up data, no stroke events were reported by 152 (60.5%), and at least one or more stroke events were reported by 99 (39.5%). The IMC has approved 115 interventionists, 29 at the first review and 86 subsequently, based upon submission and review of 631 additional contemporary cases (mean=7 cases per interventionist); 122 have approval pending submission of additional cases; 33 have been denied; 8 have been deferred; 4 have been approved for the CREST-2 Companion Registry only; and 1 is pending decision. Discussion: Rigorous evaluation and credentialing of carotid stenters in CREST-2 has been demanding, for the candidates and for the evaluators. Yet the cohort of interventionists so selected should be able to provide the high-quality stenting outcomes necessary for acceptance of the trial results.
Glypican‐1 Mediates Endothelial Hyper‐permeability in a Model of Acute Heart Failure
Isbatan, Ayman , Dull, Randal O. , Chignalia, Andréia Z. , Patel, Milan , Borlaug, Barry A.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.899.2 Get It

Accumulating evidence indicates that the lungs are active participants in the pathogenesis of heart failure (HF). Increases in left ventricular end diastolic pressure (LVEDP) leads to elevated pulmonary capillary pressure (PCP) that causes fluid filtration resulting in dyspnea and, ultimately, frank pulmonary edema (PE). However, the severity of dyspnea does not directly relate to the increase in PCP indicating that the clinical manifestation of HF cannot be solely explained by changes in Starling forces. Acute increases in PCP activate glycocalyx‐dependent signaling (endothelial mechanotransduction) that result in oxidative stress, eNOS activation and endothelial hyper‐permeability. Herein we sought to investigate if glypican‐1, a component of the glycocalyx, contributes to pressure‐dependent hyper‐permeability and PE in a model of acute HF. The isolated perfused lung preparation was used to simulate acute HF in male CD‐1 (wild type, WT) and glypican‐1 knockout (Gpc‐1 KO) mice (6 weeks old). Briefly, mice were anesthetized with isoflurane, tracheostomized and mechanically ventilated. Pulmonary artery and left atria were cannulated and in‐line pressure transducers recorded arterial and left atrial pressure; lungs were perfused at 2 mL/min with a Krebs‐Ringer 3% BSA buffer. Control experiments were done setting left atria pressure (P LA ) at 3 cm H2O for 10 minutes; acute heart failure was simulated by setting P LA at 10 cm H2O for 10 minutes. Lung edema was assessed by lung wet‐to‐dry ratio; reactive oxygen species (ROS) production and eNOS activation were assessed as indices of mechanotransduction activation by lucigenin enhanced chemiluminescence and immunoblotting, respectively. NADPH oxidase activity was measured by dihydroethidium fluorescence in isolated membrane‐fracions. WT and Gpc‐1 KO mice had similar increase in pulmonary artery pressure (from 8 to 10 mmHg). Deletion of glypican‐1 protected mice from pressure‐induced PE (wet‐to dry ratio [high and low pressure, respectfully] in WT: 7.3±0.3 vs 4.9±0.3 and in Gpc‐1 KO: 4.8±0.3 vs 4.8±0.2), prevented pressure‐dependen increase in NADPH oxidase activity (15% increase in WT) and in ROS production (80% increase in WT). Moreover, while WT mice showed increased eNOS activation (2‐fold) during acute HF, Gpc‐1 KO mice showed reduced eNOS activation (0.5 fold) indicating that Gpc‐1 is a determinant for mechanotransduction signaling. Taken together, these results suggest that Gpc‐1 activation by pressure leads to endothelial hyper‐permeability due to ROS and NO‐dependent pathways and contributes to PE in an in situ model of acute HF. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Relationship between cardiac output via acetylene rebreathing and echocardiography in heart failure
McCue, Meghan C., Olson, Thomas P. , Johnson, Bruce D. , Snyder, Eric M., Borlaug, Barry A.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.711.5 Get It

Our lab has demonstrated a lower cardiac output (Q) in patients with heart failure (HF) vs. controls (CTL) using acetylene rebreathing (ACET). This technique may be dependent on lung health, which is altered in HF. Therefore, we examined the relationship between Q from echocardiography (echo) and Q from ACET at rest and during exercise. Additionally, we examined the relationship between stroke volume (SV) estimated from O 2 pulse compared to SV by ACET (SV A ). 26 controls (CTL) and 18 HF patients with preserved ejection fraction (EF) completed an exercise test on a cycle ergometer. Lung conductance was measured by lung diffusion for carbon monoxide (DL CO ). Measures of Q (Q A , Acetylene rebreathe; Q E , transthoracic echo), heart rate (HR, 12‐lead ECG), and oxygen consumption (VO 2 , metabolic cart) were taken at rest and peak exercise. Stroke volume (SV) and O 2 pulse were calculated as Q/HR and VO 2 /HR, respectively. HF patients had lower DL CO compared to CTL (Rest: DL CO =11±0.5 vs 14±0.6 ml/min/mmHg, p<0.05). At rest and exercise, Q E was moderately correlated with Q A in CTL (Rest: r=0.47; Pk Ex: r=0.51, p<0.05) and HF (rest: r=0.47; Pk Ex: r=0.77, p<0.05). O 2 pulse was significantly related to SV A at rest and exercise in CTL (Rest: r=0.76; Pk Ex: r=0.81, p<0.05) and HF (Rest: r=0.81; Pk Ex: r=0.82, p<0.05). Cardiac function assessed via ACET is related to cardiac function by echo and O 2 pulse in patients with HF with preserved EF.
Relationship between oxygen pulse and echocardiography in heart failure with preserved ejection fraction
McCue, Meghan C., Olson, Thomas P. , Johnson, Bruce D. , Snyder, Eric M., Borlaug, Barry A.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.711.4 Get It

Purpose Oxygen pulse (O 2 pulse) is often used clinically as a surrogate for stroke volume during cardiopulmonary exercise testing; however, little data exists on the validity of this measure in patient populations (e.g. heart failure with preserved ejection fraction – HFpEF). Therefore, the purpose of this study was to examine the relationship between O 2 pulse and stroke volume (SV) measured using an accepted technique, echocardiography, at rest and during exercise. Methods Eighteen HFpEF (EF=62±1%) patients and 26 healthy controls (CTL) completed an exercise test on a cycle ergometer. Average measures of oxygen consumption (VO 2 , metabolic cart), heart rate (HR, 12‐lead ECG), and SV (transthoracic echocardiography) were taken at rest and peak exercise. O 2 pulse was calculated as VO 2 divided by HR. Results O 2 pulse was significantly correlated with SV at rest and at peak exercise in CTL (r=0.60 and r=0.55, p<0.05 for both respectfully). O 2 pulse was similarly significantly correlated with SV at rest in HFpEF (r=0.58, p<0.05) whereas this relationship demonstrated a trend at peak exercise (r=0.44, p=0.06). Conclusion Our results demonstrate a moderate relationship between O 2 pulse and SV measured using echocardiography in healthy control participants at rest and during exercise. There is a similar relationship at rest in patients with HFpEF; however, this relationship is less strong during exercise.
Myosin loss and muscle wasting in an experimental ICU model: Underlying mechanisms
Diaz, Monica Llano, Gustafson, Ann‐Marie, Dworkin, Barry R., Nair, Sreekumaran K, Larsson, Lars , Ochala, Julien , Nair, Sreekumaran K, Gautel, Mathias

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.1046.3 Get It

The muscle wasting and impaired muscle function associated with critical llness in ICU patients have negative consequences for recovery from primary disease, but are also the most persistent and debilitating of problems for ICU survivors years after hospital discharge. This study aims at improving our understanding of the mechanisms underlying the muscle wasting in ICU patients by conducting time‐resolved analyses of skeletal muscle structure and function together with measurements of protein synthesis rate, myofibrillar protein and gene expression and intracellular signaling in response to post‐synaptic block of neuromuscular transmission (NMB), sedation, mechanical ventilation and muscle unloading at durations varying from hours to two wks by using a unique experimental rat ICU model. Skeletal muscle structure and function were well maintained during the first four days, followed by a dramatic and progressive decline in muscle size and function. The preferential loss of the molecular motor protein myosin and impaired forcegenerating capacity (specif force) are the major causes underlying the impaired skeletal muscle function in the ICU model. Muscle unloading due to lack of weightbearing (external unloading) and muscle membrane depolarization (internal unloading) are forwarded as very important underlying factors. Supported by the Sweish Research Council and AFM
An under‐recognized phenomenon: Myocardial volume change during the cardiac cycle
Kumar, Vinayak , Rao, Chaitanya, Ryu, Alexander J. , Gibbons, Raymond J. , Chandrasekaran, Krishnaswamy , Asirvatham, Samuel J. , Araoz, Philip A. , Oh, Jae K. , Egbe, Alexander C. , Behfar, Atta , Anavekar, Nandan S., Behfar, Atta , Asirvatham, Samuel J , Kumar, Vinayak , Manduca, Armando , Ryu, Alexander J. , Gersh, Bernard J. , Borlaug, Barry A.

Mayo Clinic

Echocardiography | June 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/echo.15093 | PMID 34085722 Get It

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney, Sara M. , Tayob, Nabihah , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Hu, Jiani , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Rugo, Hope S. , Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Briccetti, Frederick , Schneider, Bryan P. , Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy S. , DeFusco, Patricia, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Abramson, Vandana G. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero‐Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Gelber, Richard D. , Trippa, Lorenzo , Barry, William T., DeMeo, Michelle K. , Burstein, Harold J. , Krop, Ian E. , Isakoff, Steven J , Mulvey, Therese Marie , Bose, Ron , Wolff, Antonio C , Reeder-Hayes, Katherine , Rugo, Hope S , Zuckerman, Dan , Gadi, Vijayakrishna K , Cheng, Kit , Briccetti, Frederick , Schneider, Bryan , Marcom, Paul Kelly , Albain, Kathy , Tung, Nadine , Nanda, Rita , Jankowitz, Rachel C , Rimawi, Mothaffar , Abramson, Vandana G , Van Poznak, Catherine , Forero-Torres, Andres , Liu, Minetta , Ruddy, Kathryn J , Zheng, Yue , Rosenberg, Shoshana , Trippa, Lorenzo , Partridge, Ann H , Winer, Eric , Krop, Ian E , Pohlmann, Paula , Yardley, Denise Aysel , Wolff, Antonio C. , Tung, Nadine , Zheng, Yue , Partridge, Ann H. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 21 | Pages: 2375-2385

10.1200/jco.20.03398 | PMID 34077270 Get It

PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC). METHODS Patients with stage I centrally confirmed HER2+ BC were randomly assigned 3:1 to T-DM1 or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or T 80 mg/m 2 IV with H once every week × 12 weeks (4 mg/kg load →2 mg/kg), followed by H × 39 weeks (6 mg/kg once every 3 weeks). The co-primary objectives were to compare the incidence of clinically relevant toxicities (CRTs) in patients treated with T-DM1 versus TH and to evaluate iDFS in patients receiving T-DM1. RESULTS The analysis population includes all 497 patients who initiated protocol therapy (383 T-DM1 and 114 TH). CRTs were experienced by 46% of patients on T-DM1 and 47% of patients on TH ( P = .83). The 3-year iDFS for T-DM1 was 97.8% (95% CI, 96.3 to 99.3), which rejected the null hypothesis ( P < .0001). Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. CONCLUSION Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.
Growth Differentiation Factor-15, Treatment with Liraglutide, and Clinical Outcomes Among Patients with Heart Failure
Sharma, Abhinav , Greene, Stephen J. , Fudim, Marat , Ambrosy, Andrew P. , Sun, Jie‐Lena , McNulty, Steven E., Mentz, Robert J. , Felker, G. Michael , Mentz, Robert J , Vaduganathan, Muthiah , Hernandez, Adrian F. , Borlaug, Barry A. , Velazquez, Eric J. , DeVore, Adam D. , Alhanti, Brooke , Margulies, Kenneth B.

Mayo Clinic

ESC Heart Failure | June 1, 2021 | Volume: 8 | Issue: 4 | Pages: 2608-2616

10.1002/ehf2.13348 | PMID 34061470 Get It

Abstract Aims Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the ‘Functional Impact of GLP-1 for Heart Failure Treatment’ (FIGHT) study to address these knowledge gaps. Methods and results FIGHT was a randomized clinical trial testing the effect of liraglutide (vs. placebo) among 300 participants with HFrEF and a recent HHF. Multivariable regression models evaluated associations between baseline GDF-15 and change in GDF-15 (per 1000 pg/mL increase from baseline to 30 days) with clinical outcomes (at 180 days) and declines in exercise capacity (6 min walk distance ≥ 45 m). At baseline (n = 249), median GDF-15 value was 3221 pg/mL (interquartile range 1938–5511 pg/mL). Participants in the highest tertile of baseline GDF-15 were more likely to be male and have more co-morbidities. After adjustment, an increase in GDF-15 over 30 days was associated with higher risk of death or HHF [hazard ratio 1.35, 95% confidence interval (CI) 1.11–1.64]. In addition, higher baseline GDF-15 (per 1000 pg/mL until 6000 pg/mL) and an increase in GDF-15 over 30 days were associated with declining 6 min walk distance (odds ratio 1.26, 95% CI 1.02–1.55 and odds ratio 1.37, 95% CI 1.12–1.69, respectively). GDF-15 levels remained stable among participants randomized to liraglutide. Conclusions An increase in GDF-15 over 30 days among patients in HFrEF was independently associated with an increased risk of cardiovascular events and declining exercise capacity. These results support the value of longitudinal GDF-15 trajectory in informing risk of heart failure disease progression.
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction
Sorimachi, Hidemi, Verbrugge, Frederik H. , Omote, Kazunori , Reddy, Yogesh N.V. , Takahashi, Naoki , Sunagawa, Kenji , Obokata, Masaru , Nishimura, Rick , Verbrugge, Frederik H , Takahashi, Naoki , Burkhoff, Daniel , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | May 30, 2021 | Volume: 23 | Issue: 10 | Pages: 1648-1658

10.1002/ejhf.2254 | PMID 34053158 Get It

Abstract Aims Circulating blood volume is functionally divided between the unstressed volume, which fills the vascular space, and stressed blood volume (SBV), which generates vascular wall tension and intravascular pressure. With decreases in venous capacitance, blood functionally shifts to the SBV, increasing central venous pressure and pulmonary venous pressures. Obesity is associated with both elevated venous pressure and heart failure with preserved ejection fraction (HFpEF). To explore the mechanisms underlying this association, we evaluated relationships between blood volume distribution, venous compliance, and body mass in patients with and without HFpEF. Methods and results Subjects with HFpEF ( n = 62) and non‐cardiac dyspnoea (NCD) ( n = 79) underwent invasive haemodynamic exercise testing with echocardiography. SBV was estimated (eSBV) from measured haemodynamic variables fit to a comprehensive cardiovascular model. Compared to NCD, patients with HFpEF displayed a leftward‐shifted central venous pressure–dimension relationship, indicating reduced venous compliance. eSBV was 81% higher at rest and 69% higher during exercise in HFpEF than NCD (both P < 0.0001), indicating reduced venous capacitance. Despite greater augmented eSBV with exercise, the increase in cardiac output was reduced in HFpEF, suggesting operation on the plateau of the Starling curve. Exercise eSBV was directly correlated with higher body mass index (r = 0.77, P < 0.0001) and inversely correlated with right ventricular–pulmonary arterial coupling (r = −0.57, all P < 0.0001). Conclusions Patients with HFpEF display reductions in systemic venous compliance and increased eSBV related to reduced venous capacitance, abnormalities in right ventricular–pulmonary artery interaction, and increased body fat. These data provide new evidence supporting an important role of venous dysfunction in obesity‐related HFpEF and suggest that therapies that improve venous function may hold promise to improve clinical status in this cohort.